RA Capital Management’s Solid Biosciences SLDB Stock Holding History

RA Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$120M	Buy	12,036,126 +2,696,148	+29%	+$20.4M	1.04%	25
2026 Q1	$67.2M	Buy	9,339,978 +3,528,555	+61%	+$22.7M	0.71%	29
2025 Q4	$32.8M	Hold	5,811,423	–	–	0.34%	44
2025 Q3	$35.9M	Buy	5,811,423 +100	+0%	+$585	0.44%	34
2025 Q2	$28.3M	Buy	5,811,323 +1,480,877	+34%	+$5.24M	0.48%	32
2025 Q1	$16M	Hold	4,330,446	–	–	0.27%	51
2024 Q4	$17.3M	Hold	4,330,446	–	–	0.23%	62
2024 Q3	$30.2M	Hold	4,330,446	–	–	0.35%	48
2024 Q2	$24.6M	Hold	4,330,446	–	–	0.32%	47
2024 Q1	$57.7M	Buy	4,330,446 +904,160	+26%	+$8.46M	0.73%	38
2023 Q4	$21M	Hold	3,426,286	–	–	0.33%	48
2023 Q3	$8.63M	Hold	3,426,286	–	–	0.17%	57
2023 Q2	$18M	Hold	3,426,286	–	–	0.34%	46
2023 Q1	$16.2M	Hold	3,426,286	–	–	0.37%	49
2022 Q4	$18.4M	Buy	3,426,286 +2,601,761	+316%	+$17.1M	0.37%	46
2022 Q3	$5.77M	Hold	824,525	–	–	0.12%	67
2022 Q2	$7.61M	Hold	824,525	–	–	0.2%	63
2022 Q1	$14.8M	Hold	824,525	–	–	0.32%	63
2021 Q4	$21.6M	Hold	824,525	–	–	0.38%	59
2021 Q3	$29.6M	Hold	824,525	–	–	0.41%	52
2021 Q2	$45.3M	Hold	824,525	–	–	0.73%	46
2021 Q1	$68.4M	Buy	824,525 +159,420	+24%	+$17.6M	1.03%	32
2020 Q4	$75.6M	Buy	665,105 +360,361	+118%	+$22.8M	1.06%	29
2020 Q3	$9.28M	Hold	304,744	–	–	0.17%	60
2020 Q2	$13.4M	Hold	304,744	–	–	0.26%	47
2020 Q1	$10.9M	Hold	304,744	–	–	0.35%	39
2019 Q4	$20.3M	Hold	304,744	–	–	0.62%	26
2019 Q3	$47.3M	Buy	304,744 +125,448	+70%	+$14.2M	2.82%	10
2019 Q2	$21.3M	Hold	179,296	–	–	1.14%	20
2019 Q1	$24.7M	Hold	179,296	–	–	1.07%	25
2018 Q4	$72.1M	Hold	179,296	–	–	4.2%	8
2018 Q3	$127M	Hold	179,296	–	–	6.78%	3
2018 Q2	$95.8M	Hold	179,296	–	–	6.22%	3
2018 Q1	$20.2M	Buy	+179,296	New	+$60.5M	1.55%	15

Other funds holding SLDB

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RA Capital Management's SLDB Position: Q2 2026 in Review

RA Capital Management increased its Solid Biosciences (SLDB) stake by 29% in Q2 2026, buying an estimated $20.4M and bringing the position to 12,036,126 shares worth $120M. The position accounts for 1.04% of the portfolio, ranked #25.

RA Capital Management first reported a position in SLDB in Q1 2018 and has held it in 34 quarters since. The position peaked at $127M in Q3 2018. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

RA Capital Management held 12,036,126 shares of Solid Biosciences worth $120M as of Q2 2026.
RA Capital Management bought 2,696,148 Solid Biosciences shares in Q2 2026, an estimated $20.4M.
Solid Biosciences made up 1.04% of RA Capital Management's portfolio in Q2 2026, its #25 holding.
RA Capital Management first reported a position in Solid Biosciences in Q1 2018 and has held it in 34 quarters since.
RA Capital Management's Solid Biosciences position peaked at $127M in Q3 2018.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.